Vertex Announces Expanded Reimbursement Agreement in Australia for TRIKAFTA® for Children with Cystic Fibrosis Ages 2 through 5 Years Old with at Least One F508del Mutation in the CFTR Gene

July 29, 2024 Health Trends, Health Trends - Australia

– With this reimbursement, approximately 100 children with cystic fibrosis in Australia
will become eligible for a CFTR modulator for the first time –

SYDNEY, 29 July 2024 – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that as of 1 August…

Source link

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.

Vertex Announces Expanded Reimbursement Agreement in Australia for TRIKAFTA® for Children with Cystic Fibrosis Ages 2 through 5 Years Old with at Least One F508del Mutation in the CFTR Gene

Recent Posts

Recent Comments